Patent · US Active

Compositions and methods

US9795663B2 · kind B2 · utility

0Cited by

1References

3Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Pascal Mettens · Rixensart, BE
James Raymond Brown · Berwyn, US
Dennis Murphy · Collegeville, US

Key dates

Filing date	Jun 28, 2013
Grant date	Oct 24, 2017
Priority date	—
Expiry date	Jun 28, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/35
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.